< 1 minute read
Sep. 18, 2021

PF-05221304: A Liver-Targeted Acetyl-CoA Carboxylase Inhibitor


liver-targeted acetyl-CoA carboxylase inhibitor oral hepatoselective activity obeserved in HV from opt. of prior candidate for liver uptake J. Med. Chem., Sep. 18, 2020 Pfizer, Cambridge, MA / Groton, CT

Drug Hunter Team

PF-05221304 is a liver targeted inhibitor of acetyl-CoA carboxylase (ACC). ACC is a key regulator of lipid metabolism, and there has been significant interest in ACC inhibitors for the treatment of multiple indications including NASH and diabetes. Pfizer previously took a systemic ACC inhibitor into the clinic (PF-05175157), which was found [...]



Other molecules you may be interested in